A 6-Month, Randomized, Double-Blind, Placebo And Positive-Controlled Phase 2b Study To Evaluate The Effect Of Various Doses Of CP-945,598 On Weight Loss In Obese Subjects.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Otenabant (Primary) ; Sibutramine
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Pfizer
- 18 Aug 2009 Actual patient number (282) added as reported by ClinicalTrials.gov.
- 30 Aug 2006 Status change
- 11 Jan 2006 New trial record.